RecruitingPhase 2NCT06465433
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
An Open-Label, Multicenter, Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Sponsor
Incyte Corporation
Enrollment
25 participants
Start Date
Nov 8, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
This extension study is designed to enroll participants with hematologic malignancies who are receiving clinical benefit from tafasitamab treatment in a parent study with tafasitamab..
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria6
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Having been enrolled and is still receiving treatment with tafasitamab at the end of a parent tafasitamab clinical study.
- Is tolerating tafasitamab treatment at the dose specified in the parent protocol as assessed by the Investigator.
- Is in complete/partial response or stable disease and is receiving clinical benefit from treatment with tafasitamab in the parent study, as assessed by the Investigator.
- Has demonstrated compliance, as assessed by the Investigator, with the parent protocol requirements.
- Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.
Exclusion Criteria6
- Patient who is legally institutionalized, or under judicial protection.
- Has met one or more criteria for permanent tafasitamab treatment discontinuation as stipulated in the parent protocol.
- Able to access tafasitamab outside a clinical study.
- Patient with an uncontrolled intercurrent illness or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol.
- A female patient who is pregnant confirmed by a pregnancy test prior to enrollment, breastfeeding, or a woman of childbearing potential (WOCBP) who does not agree to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment, and does not refrain from donating oocytes during this period.
- A male patient who does not agree to use contraception as detailed in the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study treatment (if they have a heterosexual partner who is a woman of childbearing potential) and who does not refrain from donating sperm during this period.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTafasitamab
Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06465433
Related Trials
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873777 locations
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893121 locations
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
NCT054704911 location
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545142 locations
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
NCT057241211 location